PMID: 3762973Nov 1, 1986Paper

Low-dose L-dopa therapy in Parkinson's disease: a 6-year follow-up study

Neurology
W H PoeweG M Stern

Abstract

Thirty-five patients with early mild Parkinson's disease were treated from the outset with small doses of L-dopa (mean dose, 396 to 454 mg daily) and a peripheral decarboxylase inhibitor, for a mean of 6 years. Overall mortality ratio was 1.2:1, worse for women than for men. After 6 years of treatment, only one-third of patients were better, and drug-related complications were common (peak-dose dyskinesias in 54% of patients, off-period dystonia 20%, wearing-off effects 52%, on-off oscillations 6%, visual hallucinations and toxic confusional states 17%). We found no evidence that long-term results were markedly improved with low-dose regimens.

Citations

Sep 29, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·E LugingerW Poewe
Jun 8, 2001·Movement Disorders : Official Journal of the Movement Disorder Society·J E Ahlskog, M D Muenter
Nov 30, 2006·Journal of Neurology·Werner Poewe
Nov 26, 2010·Journal of Neurology·E HametnerW Poewe
Oct 3, 2001·Current Treatment Options in Neurology·Stewart A. Factor
Jan 12, 2012·Neuroscience Bulletin·Ruiping Xia, Zhi-Hong Mao
Sep 15, 1996·Journal of the Neurological Sciences·O BandmannA E Harding
Jan 1, 1994·Pharmacology & Therapeutics·M E GötzM B Youdim
Sep 5, 2001·Neurologic Clinics·J E Ahlskog
Aug 8, 2001·Parkinsonism & Related Disorders·J G Nutt
May 20, 2008·Brain : a Journal of Neurology·Joohyung LeeMalcolm K Horne
Feb 5, 2003·Clinical Neuropharmacology·Ruth DjaldettiEldad Melamed
Jul 15, 2004·Clinical Neuropharmacology·Pedrox J García RuizAntonio Vázquez
Mar 1, 1989·Journal of Neurology, Neurosurgery, and Psychiatry·M A HelyG A Broe
Jun 1, 1994·Journal of Neurology, Neurosurgery, and Psychiatry·C D Marsden
Mar 25, 2000·Drugs & Aging·D Lambert, C H Waters
Feb 19, 2011·Parkinson's Disease·Sara VaraneseAlessandro Di Rocco
Feb 7, 2014·Neurodegenerative Disease Management·Talene A Yacoubian
Apr 24, 2014·Drugs·Matthias LöhleAnthony H V Schapira
Aug 19, 1999·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·P J Blanchet
Aug 31, 2002·Current Medical Research and Opinion·C Lebrun-Frenay, M Borg
Feb 5, 2009·Brain Injury : [BI]·Esteban A FridmanRoss Zafonte
Mar 4, 2010·Movement Disorders : Official Journal of the Movement Disorder Society·Elisabeth WolfWerner Poewe
Feb 4, 2010·Parkinsonism & Related Disorders·Werner Poewe, Philipp Mahlknecht
Sep 24, 2009·Journal of the Neurological Sciences·Matthias Löhle, Heinz Reichmann
Sep 28, 2007·Journal of the Neurological Sciences·Roongroj Bhidayasiri, Daniel D Truong
Jun 26, 2007·Disease-a-month : DM·Amy Kessler, Michael Rezak
Apr 12, 2005·Movement Disorders : Official Journal of the Movement Disorder Society·Joseph Jankovic
Oct 3, 2006·Movement Disorders : Official Journal of the Movement Disorder Society·Olivier RascolUNKNOWN Parkinson REGAIN Study Group
Jan 1, 1989·Acta Neurologica Scandinavica. Supplementum·R J Hardie

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.